Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 4/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | ESR1 | P03372 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.48 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.47 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.47 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1688854 | 0.92 | TDP1 (0.61) | TDP1RAB9AALDH1A1NPC1MAPT | |
| SCHEMBL16020464 | 0.86 | ALDH1A1 (0.50) | TDP1RAB9AALDH1A1MAPTGAA | |
| SCHEMBL17896517 | 0.86 | TDP1 (0.55) | TDP1RAB9AALDH1A1NPC1MAPT | |
| SCHEMBL9768509 | 0.85 | ESR1 (0.63) | TDP1RAB9AALDH1A1NPC1MAPT | |
| SCHEMBL394866 | 0.83 | TDP1 (0.52) | TDP1RAB9AALDH1A1NPC1MAPT | |
| SCHEMBL31065663 | 0.83 | ESR1 (0.43) | TDP1RAB9AALDH1A1NPC1MAPT | |
| SCHEMBL513612 | 0.82 | TDP1 (0.61) | TDP1RAB9AALDH1A1NPC1MAPT | |
| SCHEMBL2652364 | 0.82 | LMNA (0.58) | TDP1RAB9AALDH1A1NPC1GAA | |
| SCHEMBL9464103 | 0.82 | ADRB2 (0.50) | TDP1RAB9AALDH1A1NPC1MAPT | |
| SCHEMBL20127259 | 0.81 | CA1 (0.58) | TDP1RAB9AALDH1A1NPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190382422-A1 | SALICYLIC ACID DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, COMPOSITION THEREOF AND METHOD OF USE THEREOF | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2019-12-19 | — | — | US | disclosed |
| US-10377780-B2 | Salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2019-08-13 | — | — | US | disclosed |
| US-20170267704-A1 | SALICYLIC ACID DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, COMPOSITION THEREOF AND METHOD OF USE THEREOF | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2017-09-21 | — | — | US | disclosed |
| US-20170267704-A1 | SALICYLIC ACID DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, COMPOSITION THEREOF AND METHOD OF USE THEREOF | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2017-09-21 | — | — | US | disclosed |
| US-9650399-B2 | Salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2017-05-16 | — | — | US | disclosed |
| US-9650399-B2 | Salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2017-05-16 | — | — | US | disclosed |
| US-20160235866-A1 | MRI CONTRAST AGENTS FOR CELL LABELING | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2016-08-18 | — | — | US | disclosed |
| US-20160235866-A1 | MRI CONTRAST AGENTS FOR CELL LABELING | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2016-08-18 | — | — | US | disclosed |
| US-20150158894-A1 | SALICYCLIC ACID DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, COMPOSITION THEREOF AND METHOD OF USE THEREOF | UTI LIMITED PARTNERSHIP (CA) | 2015-06-11 | — | — | US | disclosed |
| US-20150158894-A1 | SALICYCLIC ACID DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, COMPOSITION THEREOF AND METHOD OF USE THEREOF | UTI LIMITED PARTNERSHIP (CA) | 2015-06-11 | — | — | US | disclosed |
| WO-2015048912-A1 | MRI CONTRAST AGENTS FOR CELL LABELING | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2015-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190382422-A1 | SALICYLIC ACID DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, COMPOSITION THEREOF AND METHOD OF USE THEREOF | STAT3, STAT5A, STAT6 | TDP1 2922/4885RAB9A 3373/4885ALDH1A1 722/4885 |
| US-20170267704-A1 | SALICYLIC ACID DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, COMPOSITION THEREOF AND METHOD OF USE THEREOF | STAT3, STAT5A, STAT6 | TDP1 2922/4885RAB9A 3373/4885ALDH1A1 722/4885 |
| US-20160235866-A1 | MRI CONTRAST AGENTS FOR CELL LABELING | MPI, HMBS, TSPO | TDP1 1598/4885RAB9A 1054/4885ALDH1A1 1750/4885 |
| US-10377780-B2 | Salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof | STAT3, STAT5A, STAT6 | TDP1 2922/4885RAB9A 3373/4885ALDH1A1 722/4885 |
| US-20150158894-A1 | SALICYCLIC ACID DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, COMPOSITION THEREOF AND METHOD OF USE THEREOF | STAT3, STAT5A, JAK2 | TDP1 2863/4885RAB9A 2792/4885ALDH1A1 836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.